Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News out today:
Rolls-Royce today welcomed the announcement that the Australian Government would be investing in its ongoing AUKUS preparations. This supplements the expansion funding already committed by the UK Ministry of Defence (MOD).
To meet the growth in demand from the Royal Navy, which includes AUKUS delivery commitments, work is already underway to double the size of the Rolls-Royce Submarines site in Raynesway, Derby.
Now jointly funded by UK MOD and the Australian Department of Defence, the expansion work announced last summer will create over 1,000 new jobs in Derby across a range of disciplines, including manufacturing and engineering. It will also see new manufacturing and office facilities being built on recently acquired land surrounding the existing Raynesway site.
In March 2023 it was confirmed that Rolls-Royce Submarines would provide all the nuclear reactor plants that will power new attack submarines as part of the tri-lateral agreement between Australia, the UK and US.
Rolls-Royce Submarines President Steve Carlier said:
Last year we were proud to welcome the Hon Richard Marles MP, Australia’s Deputy Prime Minister and Minister for Defence, and UK Defence Secretary Grant Shapps, to our Raynesway site to showcase some of the world-class manufacturing and engineering capabilities we have developed over the last 60 years.
This commitment of funding to our existing expansion work shows the trust Australia places on our nuclear expertise and our ability to deliver. We look forward to working with the Australian Submarine Agency to support them in building their own fleet of nuclear-powered submarines.”
Grant Shapps MP, UK Secretary of State for Defence, said:
In a more dangerous world, today’s announcement symbolises the huge confidence our close partner Australia has in our world-leading defence industry, including companies such as BAE Systems and Rolls-Royce.
Through these collaborations, British industry will grow, and thousands of jobs created across the country, delivering security and prosperity to our two nations.”
To support preparation for AUKUS and to meet the additional commitments to the MOD, Rolls-Royce recently announced the opening of two satellite offices in Glasgow and Cardiff. The locations were selected to help access the skilled talent pools in both regions, with more than 100 jobs being created in each city.
To further ensure a steady pipeline of future talent into the industry, Rolls-Royce opened a new Nuclear Skills Academy in Derby in 2022. It will provide 200 apprenticeships each year for at least the next decade.
Rolls-Royce Submarines currently employs more than 4,000 people and designs, manufactures and provides in-service support to the pressurised water reactors that power every boat in the Royal Navy’s submarine fleet.
Rolls-Royce is currently supporting the existing Astute and Dreadnought boat build programmes through the delivery of reactor plant and associated components. Additionally, it provides frontline support across the world for reactor plant equipment from its Operations Centre in Derby and supports the submarines when in the Barrow-in-Furness shipyard and the naval bases at Devonport and Faslane.
I've been in all 3 since 2019 and now is the 2nd most exciting time as a shareholder.
The most exciting time was 2019 when I bought 850K RLLCF at .0001 without knowing what I was buying and 2 months later it blewup as high as .47 but I wasn't able to sell until it dropped to .17 to .12 - TDAmeritrade cost me over a quarter million dollars because they didn't have the shares they sold me. Still did extremely well on it.
Both RYCEY and RYCEF are continuing upward in a very very strong uptrend. RLLCF is lagging way behind but presents the best bang for your buck right now in Rolls Royce, my personal, non-professional, not giving advice price target for RLLCF is 50 cents which would be a moonshot from less than half a penny but it has happened before in 2019 so why not 2024???? Great place to let $100 rest for a while IMO
Amazing how a shtshow like CISO doesn't say a word until after they RS the stock. Almost right out of the pinky scam stocks a barrage of useless BS "awards" & "recognition" that mean absolutely nothing but peeps buy the BS
Me too right before they expired. I had $72.53 in and cashed out $1797.50 in 7 months
monthly cash distribution $0.041278 per Unit, based primarily upon the reported production of the Trust's subject interests (the "Subject Interests") during the month of January 2024. The distribution is payable April 12, 2024, to the Unit Holders of record as of March 28, 2024.
I buy in Etrade with no extra fee over the commish. I can also buy on TDAmeritrade but they are ripping me off since Chuckie Schwab instituted a $44 upcharge over and above the commish to rip off their customers on all foreign tickers. Fidelity also rips their customers off with the same insane upcharge SO NOW I ONLY BUY "F" TICKERS THRU ETRADE.
They obviously aren't very motivated or they would have closed the deal already.
They must have to votes for the extension since they only left 3 days to make it work.
I agree and it is worth the wait required IMO
Wanna be a super genius? Make sure you have some RLLCF also - last big run ran to 47 cents and should do the same once they announce resumption of divis.
Under half a penny worth the gamble to me but them again I still hold 39K shares at .0001
Priced at a nickel weeeeee crash, burn, over
Didn't like it in the .60 and see even less to like at .44 -
I have only one question - Will it be a quick BK or a slow drawn out worthless attempt to infuse some sort of actual value?
Anything is possible but not likely when XBI only holds 1.2% of ARDX
Let's see if ARDX can claw its way toward even for the day.
Well obviously someone with a much larger stake didn't take very kindly to Rep Carter's legislation unless shareholders are losing faith in the C suite who seem only concerned about handing out round after round of shares to insiders and new hires before they show they are even worth a paycheck let along freebies.
Thanks, now I have a better understanding of the process, Carter is actually working on the patients behalf, I can appreciate that.
The $3K a month for X seems unreasonably high - Glad I'm not one of the poor patients or a patient at all.
Like most things gooberment related, I just can't think Stupid like they can. Why should any representative be involved with such things? Shouldn't the most affordable drug be used since they are spending my money? If the makers of X want to limit their sales to self pays it is not the gooberments business.
I have lost faith in ARDX and have begun reducing holdings in all accounts.
I'm a slower reader but what I take from this is that Rep Earl L. "Butthead" Carter is in someone's pocket looking to delay oral binders until someone he must know gets an approved IV binder. Seem very contrary to the needs of the kidney community's needs NOW not 10 years from now.
Where do people find these fools to pretend to represent us?
Please explain how I'm wrong.
YUGGGGE MERGER NEWS OUT - CAUGHT A WINNER HERE
My bet is they close below a buck by tomorrow afternoon.
It's just a worthless ticker run by imbeciles from what I can see.
Feb PR:
Rolls-Royce (LSE: RR., ADR: RYCEY) today announces a commitment by Vietjet Air for 20 Trent 7000 powered A330neo, which will complement the airline’s existing widebody fleet of seven Trent 700 powered A330ceo aircraft.
With a laser focus on sustainability, Vietjet Air has committed to the A330neo/Trent 7000 combination as it delivers a 14% better fuel burn per seat, whilst significantly lowering emissions. The reduction in emissions will allow the airline to avoid more than one hundred thousand tons of CO2 over the lifetime of each aircraft.
The Trent 7000 draws on the technology and experience of the most advanced family of engines in the world. As the latest member of the Trent family, the Trent 7000 is based on Trent XWB technology and has delivered exceptional reliability since its entry into service.
Ewen McDonald, Chief Customer Officer, Rolls-Royce – Civil Aerospace, said:
Today’s commitment demonstrates Vietjet Air’s confidence in the power of the Trent 7000 to deliver significant sustainability gains alongside a reliable and consistent customer experience. We are proud to continue supporting Vietjet Air as they expand their operation responsibly and sustainably over the coming years.”
Vietjet Air, Chief Executive Officer, Dinh Viet Phuong, said:
The combination of modern Trent 7000 engines on the newest generation of Airbus A330neo will help Vietjet Air reach new technological heights, improve the quality of our flights, and increase the reliability and efficiency of our operations. Specifically, the addition of newest generation, high-efficiency Rolls-Royce engines will contribute significantly to Vietjet Air’s ESG plan to achieve net zero emissions by 2050.”
Historically they pay divis twice a year, but they are not yet declaring any.
Shareholder payments: We are not making shareholder payments for 2023. As we shared at our capital markets
day in November 2023, once we are comfortably within an investment grade profile and the strength of our balance
sheet is assured, we are committed to reinstating and growing shareholder distributions.
I have complete faith this non-company AZ ticker can break below a buck before the end of next week.
THEY GOT NOTHIN AND IS RUN BY CLOWNS.
That's music to me ears. It was absolutely destroyed today.
Been nibbling this morning gotta be something if the price targets are maintained in the $30s
EACPW flaming out upon liquidation news
Sold some ADOCW this morning pre-market @ .065
Yes, once the divis start flowing again this could get very very interesting.
How ya been? Been years
I was munching on a bunch of RLLCF today, just feel its time to buy some of them again.
$5 was tough but it should move up easier now that it broke the mental resistance
25% of today's volume was me adding for eventual payday. Won't be like last time since I have a higher starting price, last time was in at .0001 but this should be a fair return when it's time.
What a waste of a RS. Ratio isn't high enough to keep it over a buck for 10 straight trading days. If they had actual management they would have just dropped to pinks where it truly belongs. Horrible horrible performance by a truly inept CEO and BOD.
Don't see it happening, the lil fat man and his circus can't even hold an annual meeting - Next possible date is now in JUNE.... they started wayyyy back in October.
The auditors got the hell out of there.
They have nothing positive to report so I expect they won't report until they are threatened with being tossed off Nasdaq YET AGAIN.
The lil fat dude is almost dumb enough to work for poser prez.
8K announcing $50mil term loan into 2027, see if they can strings a couple green days together before they shoot themselves in the foot.
Bid sitting at .94 - I always bid 30-50% off offering price. Either it comes to me or I pass.
Unsolicited Approach from Possible Strategic Acquiror, Launch of Formal Sale Process, and Update on Financing
Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney
disease to drive improved patient outcomes and advance value-based care provides the following update in regard to an unsolicited approach from a possible
strategic acquiror, launch of a Formal Sale Process, and its advanced financing activities.
Formal Sale Process
Renalytix has received an unsolicited approach from a large and well-capitalised publicly listed strategic diagnostics company, which is in the process of
evaluating an acquisition of the entire issued, and to be issued, share capital of the Company.
Therefore, the Company has commenced a review of all available options, including a possible sale of the Company and/or its assets, and has commenced a
formal sale process (as referred to in Note 2 on Rule 2.6 of the City Code on Takeovers and Mergers) (the “Formal Sale Process”). The Formal Sale Process will
enable the Board and its advisers to conduct an orderly process and engage more widely with all potentially interested parties, with a view to optimising the
outcome for Renalytix’s shareholders. It remains possible that, following completion of the Formal Sale Process, the Board will consider that Renalytix and its
shareholders would be best served by alternative strategic options available to the Company, including by Renalytix continuing to trade on AIM and Nasdaq as
an independent entity.
The Takeover Panel has granted a dispensation from the requirements of Rules 2.4(a), 2.4(b) and 2.6(a) of the Takeover Code such that any interested party
participating in the Formal Sale Process will not be required to be publicly identified as a result of this announcement and will not be subject to the 28 day
deadline referred to in Rule 2.6(a) of the Takeover Code for so long as it is participating in the Formal Sale Process.
The Board is working with and intends to appoint Stifel Nicolaus Europe Limited (“Stifel”) as Sole Financial Adviser and Rule 3 Adviser with respect to the
Formal Sale Process and any offer for the Company that may be forthcoming.
Parties interested in submitting any expression of interest or other proposal relating to any strategic option for the Company, should contact Stifel via the
contact details given below.
It is currently expected that any party interested in submitting any form of proposal for consideration within the Formal Sale Process will, at the appropriate
time, be required to enter into a non-disclosure agreement and standstill arrangement with the Company on terms satisfactory to the Board and on the same
terms, in all material respects, as other interested parties before being permitted to participate in the process. The Company then intends to provide such
interested parties with certain information on its business, following which interested parties shall be invited to submit their proposals to Stifel. The Company
will update the market in due course regarding timings for the Formal Sale Process. The Board reserves the right to alter any aspect of the process as outlined
above or to terminate the process at any time and in such cases will make an announcement
as appropriate. The Board also reserves the right to reject any approach or terminate discussions with any interested party at any time.
Shareholders are advised that this announcement does not represent a firm intention by any party to make an offer under Rule 2.7 of the Takeover Code and
there can be no certainty that any offers will be made as a result of the Formal Sale Process, that any sale, strategic investment or other transaction will be
concluded, nor as to the terms on which any offer, strategic investment or other transaction may be made.
Following this announcement, the Company is now considered to be in an Offer Period as defined in the Takeover Code, and the dealing disclosure
requirements set out below will apply.
Further announcements will be made in due course.
Financing Discussions
As part of a review of funding options currently being explored, the directors of Renalytix (the “Board”) are considering possible sources of funding, including
equity and debt. The Company is in advanced discussions with certain existing shareholders as well as potential new equity and debt providers.
The Company has cash on hand of $2.3 million and marketable securities of approximately $1.4 million as at 3 March 2024. As reported on February 15, 2024,
operating cost reductions commenced during the fiscal second quarter continued with a fiscal third quarter cash burn target approximately 33% less than in
the prior quarter and approximately 50% less than in the first quarter of fiscal 2024. The Company expects existing cash resources to finance the business
through April 2024, foregoing the possible Sale of the Company and/or its assets, or successful completion of the advanced financing activities noted above.
For further information, please contact:
Renalytix plc
James McCullough, CEO
www.renalytix.com
Via Walbrook PR
Stifel (Nomad and Joint Broker to Renalytix)
Nicholas Moore / Nick Harland / Samira Essebiyea
Tel: 020 7710 7600
Investec Bank plc (Joint Broker)
Gary Clarence / Shalin Bhamra
Tel: 020 7597 4000
Walbrook PR Limited
Paul McManus / Alice Woodings / Charlotte Edgar
Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541893 / 07407 804654 / 07884 664686
CapComm Partners
Peter DeNardo
Tel: 415-389-6400 or investors@renalytix.com
I'm looking towards $6 to recover what I put in and see what happens from there.
Definitely a smart buy back when I purchased and your .70s very nice
MEGA SUPER ULTRA HIGH RISK
Just bought some lotto tickets on EACPW @ .0044 - deal was terminated today
Know nothing about it but peeled off some shares this morning at a penny
I own it and with the right news or advancement it could fly IMO.
I'm still buying under a penny when they give em to me.
I was buying today in anticipation of the RS, a 3 to 1 is nothing which appears to show they are in alignment with shareholders. The reduction in authorized shares is a huge benefit along with the reduce OS. I think it makes it a more attractive bet going forward. Personally some of the worst performers have been Nasdaq stocks that should never have been allowed on the exchange, I think FFIE would be better served listing on the OTC.